Category: 25813-24-5

Clarke, K.; Rothwell, K. published an article in 1960, the title of the article was A kinetic study of the effect of substituents on the rate of formation of alkylpyridinium halides in nitromethane solution.Product Details of 25813-24-5 And the article contains the following content:

Rates of reaction of substituted pyridines with CH2:CHCH2Br (I), MeI, PhCH2Br, and PrBr in MeNO2 were measured at several temperatures Substituents influenced both Arrhenius parameters, E and log PZ. In general, the logarithms of the rate constants varied linearly with the dissociation constants of the bases in H2O; however, the rates for the alkoxypyridines did not fit the linear relation, presumably due to a solvent effect, and those for the 2-substituted pyridines followed a different linear relation than those for the 3- and 4-substituted compounds Plots of log k against the Hammett substituent constants gave a somewhat scattered series of points, the 3- and 4-substituted compounds giving approx. linear relations with different slopes. The ortho effect influenced the activation energy, rather than the PZ factor. Primary steric hindrance was deemed important in the ortho effect. Changes in the free energy of ionization of pyridines and of activation for the Menschutkin reaction brought about by 2 substituents were algebraic sums of the changes brought about by the 2 groups individually, except in the case of 2,6- and 2,3-disubstituted compounds Rate constants (k × 104) at 60°, energies of activation (kcal./mole), and log PZ for reactions with I, and pK for ionization of the pyridine bases were (substituents shown): 2-Me, 7.53, 13.62, 5.83, 5.97; 3-Me, 71.4, 12.52, 6.06, 5.68; 4-Me, 81.7, 12.44, 6.07, 6.02; 2,3-Me2, 7.34, 13.86, 5.96, 6.60; 2,4-Me2, 14.6, 13.20, 5.82, 6.72; 2,5-Me2, 12.4, 13.31, 5.83, 6.47; 2,6-Me2, 0.18, -, -, 6.77; 3,4-Me2, 131.5, 12.20, 6.13, 6.52; 3,5-Me2 (II), 109.1, 12.37, 6.14, 6.14; 2-Et, 3.65, 13.94, 5.71, 5.99; 4-Et, 85.0, 12.46, 6.11, 6.02; 2,4,6-Me3, 0.31, -, -, 7.48; 2-OMe, -, -, – (no reaction), 3.40; 3-OMe, 41.3, 12.73, 5.96, 4.91; 4-OMe(III), 91.9, 12.38, 6.08, 6.55; 3-OEt, 45.7, -, -, -, 4-OEt, 104.0, 12.44, 6.18, 6.67; 3-Br, 5-OMe (IV), 5.56, 13.72, 5.75, -; 3-Br, 5-OEt (V), 6.38, 13.69, 5.78, -: 3-F, 5.69, 13.76, 5.77, 3.0; 3-Cl, 5.45, 13.72, 5.74, 2.84; 3-Br (VI), 5.87, 13.67, 5.13, 2.84; 3-CO2Et, 8.98, 13.58, 5.87, 3.35; 4-CO2Et, 10.0, 13.51, 5.87, 3.45; unsubstituted, 46.3, 12.73, 6.00, 5.17. The 2-F, 2-Cl, 3,5-Br2 (VII), 3,5-Br2 4-OMe, 3,5-Br2 4-Cl (VIII), 2-CO2Et, 4-OMe 5-NO2 (IX), and 4-OEt 5-NO2 (X) derivatives did not react with I at 60°. Kinetic measurements were made in 0.05M solution of the reactants, the extent of reaction being determined by Volhard titration of the bromide formed. VII (5 g.) in 75 ml. ether added to Me3CLi (from 1.3 g. Li) in ether at -35 to -40°, the mixture stirred 30 min., excess MeI in ether added, the ether removed, the residual paste acidified and steam-distilled, and the residue made alk. and steam-distilled gave II, b. 170.0-70.5°, m. -10°. The perbromide of pyridine hydrobromide treated by the method of Englert and McElvain (CA 23, 1901) gave, along with 3-bromo- and 3,5-dibromopyridine, a mixture of tribromopyridines from which 2,3,5-tribromopyridine, b. 160°, m. 45.0-5.5°, was isolated. VII (15 g.) refluxed 8 hrs. with MeOK (from 10 g. K) in 100 ml. MeOH, the solution filtered, acidified, and steam-distilled, the residue made alk. and steam distilled, the product extracted with ether, and HBr added gave 74% IV hydrobromide, m. 178.5-9.5°, from which IV, m. 33.5-4.0°, was liberated by addition of NaOH. V, b5 111°, m. 8.2-8.8°, was prepared similarly. VII and MeOK heated 5 min. at 140° and steam distilled gave 32% 3,5-dimethoxypyridine, isolated as the picrate; chloroplatinate m. 212-13° (decomposition) (alc. HCl). Chelidamic acid (20 g.) and 25 g. Br in H2O stirred 24 hrs., the product filtered off and decarboxylated 1 hr. at 200-240°, 15 g. PCl5 and 15 g. POCl3 added, the mixture heated 0.5 hr. at 125°, H2O added, and the mixture poured into iced aqueous KOH and steam-distilled gave 15.1 g. VIII, m. 98.0-8.5° (alc.). The latter (10 g.) added to MeOK (from 10 g. K) in 100 ml. MeOH and diluted with H2O gave 40% ether, m. 85-6° (alc.). Picolinic acid (20 g.) in 50 g. absolute EtOH and 50 g. H2SO4 refluxed 4 hrs., poured on ice, made alk. with NH3, and extracted with Et2O gave 20% Et picolinate, b47 153-4°. Et nicotinate, b21 116°, m. 9.6-10.0°, and Et isonicotinate, b21 111.5-12.0°, m. 7.0-7.5°, were similarly prepared in 80 and 40% yield, resp. Nitration of 4-hydroxypyridine (Koenigs and Freter, CA 19, 71) gave 15% 4-hydroxy-3,5-dinitropyridine, m. 315°, and no mononitro derivative The nitrate of III (2.5 g.), 10 g. fuming HNO3, and 10 g. fuming H2SO4 (containing 20% SO3) heated 24 hrs. on a steam bath gave 34% IX, m. 76.0-6.5°. X, m. 48.0-8.4°, was prepared similarly in 41% yield. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Product Details of 25813-24-5

3,5-Dibromo-4-methoxypyridine(cas:25813-24-5) belongs to pyridine-derivatives. Several pyridine derivatives play important roles in biological systems. While its biosynthesis is not fully understood, nicotinic acid (vitamin B3) occurs in some bacteria, fungi, and mammals.Product Details of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Collins, Ian; Suschitzky, Hans published an article in 1970, the title of the article was Polyhaloaromatic compounds. XIV. Nucleophilic substitution and peroxy-acid oxidation of pentabromopyridine and some of its NN-dialkylamino- and bis(NN-dialkylamino)-derivatives.Category: pyridine-derivatives And the article contains the following content:

Pentabromopyridine was treated with various nucleophiles, such as alkoxides and primary and secondary amines. In the last case, with benzene as the solvent, 2(6)-substitution occurred exclusively, whereas use of EtOH as solvent produced the 4-isomer also. In all other cases a mixture of the 4- and 6-isomer was obtained. Oxidation of pentabromopyridine with peroxytrifluoroacetic acid yielded the corresponding 1-oxide as well as three isomeric tetrabromopyridine 1-oxides by protodebromination. Oxidation of 2-N,N-dialkylaminotetrabromopyridines gave hydroxylamines by mol. rearrangement of the intermediate N-oxide, whereas the 4-isomer gave a mixture of 4-nitroso-, 4-nitro-, and 4-aminotetrabromopyridines by an established mechanism. The nitro group in tetrabromo-6-nitropyridine was readily replaced with piperidine but not that in the 4-nitro isomer. Comparisons are drawn between the reactions of polybromo- and the corresponding polychloro-, and, in some cases, polyfluoropyridines, and reasons for differences are advanced. Concurrence of protodebromination and nucleophilic substitution is discussed. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Category: pyridine-derivatives

3,5-Dibromo-4-methoxypyridine(cas:25813-24-5) belongs to pyridine-derivatives. Several pyridine derivatives play important roles in biological systems. While its biosynthesis is not fully understood, nicotinic acid (vitamin B3) occurs in some bacteria, fungi, and mammals.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 10, 2020, Smil, David; Wong, Jong Fu; Williams, Eleanor P.; Adamson, Roslin J.; Howarth, Alison; McLeod, David A.; Mamai, Ahmed; Kim, Soyoung; Wilson, Brian J.; Kiyota, Taira; Aman, Ahmed; Owen, Julie; Poda, Gennady; Horiuchi, Kurumi Y.; Kuznetsova, Ekaterina; Ma, Haiching; Hamblin, J. Nicole; Cramp, Sue; Roberts, Owen G.; Edwards, Aled M.; Uehling, David; Al-awar, Rima; Bullock, Alex N.; O’Meara, Jeff A.; Isaac, Methvin B. published an article.Recommanded Product: 3,5-Dibromo-4-methoxypyridine The title of the article was Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. And the article contained the following:

There are currently no effective chemotherapeutic drugs approved for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric cancer resident in the pons region of the brainstem. Radiation therapy is beneficial but not curative, with the condition being uniformly fatal. Anal. of the genomic landscape surrounding DIPG has revealed that activin receptor-like kinase-2 (ALK2) constitutes a potential target for therapeutic intervention given its dysregulation in the disease. An open science approach has been adopted to develop a series of potent, selective, orally bioavailable, and brain-penetrant ALK2 inhibitors based on the lead compound LDN-214117. Modest structural changes to the C-3, C-4, and C-5 position substituents of the core pyridine ring afforded compounds M4K2009, M4K2117, and M4K2163, each with a superior potency, selectivity, and/or blood-brain barrier (BBB) penetration profile. Robust in vivo pharmacokinetic (PK) properties and tolerability mark these inhibitors as advanced preclin. compounds suitable for further development and evaluation in orthotopic models of DIPG. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Recommanded Product: 3,5-Dibromo-4-methoxypyridine

The Article related to preparation alk2 inhibitor diffuse intrinsic pontine glioma, Pharmacology: Structure-Activity and other aspects.Recommanded Product: 3,5-Dibromo-4-methoxypyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 30, 2018, Robke, Lucas; Rodrigues, Tiago; Schroeder, Peter; Foley, Daniel J.; Bernardes, Goncalo J. L.; Laraia, Luca; Waldmann, Herbert published an article.Name: 3,5-Dibromo-4-methoxypyridine The title of the article was Discovery of 2,4-dimethoxypyridines as novel autophagy inhibitors. And the article contained the following:

Autophagy is a catabolic process, which mediates degradation of cellular components and has important roles in health and disease. Therefore, small mol. modulators of autophagy are in great demand. Herein, we describe a phenotypic high-content screen for autophagy inhibitors, which led to the discovery of a dimethoxypyridine-based class of autophagy inhibitors, which derive from previously reported, natural product-inspired MAP4K4 inhibitors. Comprehensive structure-activity relationship studies led to a potent compound, and biol. validation experiments indicated that the mode of action was upstream or independent of mTOR. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Name: 3,5-Dibromo-4-methoxypyridine

The Article related to dimethoxy pyridine derivative preparation autophagy inhibitor structure, Pharmacology: Structure-Activity and other aspects.Name: 3,5-Dibromo-4-methoxypyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 23, 2017, Watanabe, Atsushi; Sato, Yuuki; Ogura, Keiji; Tatsumi, Yoshiyuki published a patent.Synthetic Route of 25813-24-5 The title of the patent was Preparation of biaryl derivatives as antifungal agents and medicine containing them. And the patent contained the following:

Biaryl derivatives represented by general formula I (ring A, X1, X2, X3, Y, Z, R2a, R3, and Q are defined below) or salts thereof having excellent antifungal activity against Trichophyton, which is a major causative organism of superficial mycoses. Ring A, X1, X2, X3, Y, Z, Q, and R3 are defined as [ring A = each (un)substituted Ph or 5- or 6-membered heteroaryl each optionally fused to form (un)substituted condensed ring; Q = CH2, CF2, S(O), SO2, C(O), NH, or S; X1, X2, X3 = CR1 or N; Y = CH or N; Z = CR2b or N; R1 = H, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; R3 = H, halo, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, or aralkyl]. R2a and R2b are defined as [R2a, R2b = H, halo, HO, cyano, formyl, pentafluorosulfanyl, Q1, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-4 alkoxy-C1-4 alkyl, C1-4 alkoxy-C1-4 haloalkyl, C1-6 alkyl carbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C3-7 cycloalkyl, heterocycloalkyl, heterocycloalkyloxy, C2-6 alkenyl, C2-6 alkenyloxy, C2-6 alkenyl-C1-6 alkyl, C2-6 alkenyl-C1-6 alkoxy, C2-6 alkenyloxy-C1-4 alkoxy, C2-6 alkenyloxy-C1-4 haloalkyl, C2-6 alkenyloxy-C1-4 haloalkoxy, C2-6 alkynyl, C2-6 alkynyloxy, C2-6 alkynyl-C1-6 alkyl, C2-6 alkynyl-C1-6 alkoxy, C2-6 alkynyloxy-C1-4 alkyl, C2-6 alkynyloxy-C1-4 alkoxy, C2-6 alkynyloxy-C1-4 haloalkyl, C2-6 alkynyloxy-C1-4 haloalkoxy, NH2, C1-6 alkylthio, C1-6 haloalkylthio; ring B = each (un)substituted carbocyclic or heterocyclic ring; L = a single bond, (CH2)p, O(CH2)p, (CH2)pO, (CH2)pO(CH2)q, NRc(CH2)p , (CH2)pNRc, or (CH2)pNRc(CH2)q; p, q = 1, 2, or 3; one or a plural number of H atoms of each (CH2)p or (CH2)q is optionally substituted with halo, C1-4 alkyl, or C3-7 cycloalkyl; Rc = H or C1-6 alkyl; when Z = CR2b, R2a and R2b together with the carbon atoms to which they are bonded form each (un)substituted carbocyclic or heterocyclic ring]. The biaryl derivatives I include arylpyridine or heterocyclylpyridine derivatives, e.g. 3-phenyl-2-[(pyridin-3-yl)oxy]pyridine, 2-[(pyridin-3-yl)oxy]-3,3′-bipyridine, 5-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]isoquinoline, 8-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]quinoline, 3-(2,3-dihydrobenzofuran-7-yl)-2-[(pyridin-3-yl)oxy]pyridine, 5-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]quinoxaline, and 3-(chroman-8-yl)-2-[(pyridin-3-yl)oxy]pyridine derivatives Thus, etherification of 3-bromo-2-chloropyridine with 6-(trifluoromethyl)pyridin-3-ol in the presence of Cs2CO3 in DMSO with stirring at 120° for 18 h gave 76% 3-[(3-bromopyridin-2-yl)oxy]-6-(trifluoromethyl)pyridine (II). Coupling of II with 2-methoxyphenylboronic acid in the presence of bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]palladium(II) and Cs2CO3 in aqueous dioxane solution with stirring at 120° for 30 min under microwave irradiation gave 76% 3-(2-methoxyphenyl)-2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]pyridine (III). III showed min. inhibitory concentration of ≤0.1 μg/mL against Trichophyton mentagrophytes and T. rubrum. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Synthetic Route of 25813-24-5

The Article related to bipyridine phenylpyridine pyridylquinoline pyrimidinylpyridine heterocyclylpyridine preparation antifungal, biaryl preparation antifungal agent, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Synthetic Route of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 20, 2018, Watanabe, Atsushi; Sato, Yuki; Ogura, Keiji; Tatsumi, Yoshiyuki published a patent.Recommanded Product: 3,5-Dibromo-4-methoxypyridine The title of the patent was Preparation of biaryl derivatives as antifungal agents and medicine containing them. And the patent contained the following:

Biaryl derivatives represented by general formula I (ring A, X1, X2, X3, Y, Z, R2a, R3, and Q are defined below) or salts thereof having excellent antifungal activity against Trichophyton which is a major causative organism of superficial mycoses are prepared Ring A, X1, X2, X3, Y, Z, Q, and R3 are defined as [ring A = each (un)substituted Ph or 5- or 6-membered heteroaryl each optionally fused to form (un)substituted condensed ring; Q = CH2, CF2, S(O), SO2, C(O), NH, or S; X1, X2, X3 = CR1 or N; Y = CH or N; Z = CR2b or N; R1 = H, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; R3 = H, halo, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, or aralkyl]. R2a and R2b are defined as [R2a, R2b = H, halo, HO, cyano, formyl, pentafluorosulfanyl, Q1, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-4 alkoxy-C1-4 alkyl, C1-4 alkoxy-C1-4 haloalkyl, C1-6 alkyl carbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C3-7 cycloalkyl, heterocycloalkyl, heterocycloalkyloxy, C2-6 alkenyl, C2-6 alkenyloxy, C2-6 alkenyl-C1-6 alkyl, C2-6 alkenyl-C1-6 alkoxy, C2-6 alkenyloxy-C1-4 alkoxy, C2-6 alkenyloxy-C1-4 haloalkyl, C2-6 alkenyloxy-C1-4 haloalkoxy, C2-6 alkynyl, C2-6 alkynyloxy, C2-6 alkynyl-C1-6 alkyl, C2-6 alkynyl-C1-6 alkoxy, C2-6 alkynyloxy-C1-4 alkyl, C2-6 alkynyloxy-C1-4 alkoxy, C2-6 alkynyloxy-C1-4 haloalkyl, C2-6 alkynyloxy-C1-4 haloalkoxy, NH2, C1-6 alkylthio, C1-6 haloalkylthio; ring B = each (un)substituted carbocyclic or heterocyclic ring; L = a single bond, (CH2)p, O(CH2)p, (CH2)pO, (CH2)pO(CH2)q, NRc(CH2)p , (CH2)pNRc, or (CH2)pNRc(CH2)q; p, q = 1, 2, or 3; one or a plural number of H atoms of each (CH2)p or (CH2)q is optionally substituted with halo, C1-4 alkyl, or C3-7 cycloalkyl; Rc = H or C1-6 alkyl; when Z = CR2b, R2a and R2b together with the carbon atoms to which they are bonded form each (un)substituted carbocyclic or heterocyclic ring]. The biaryl derivatives I include arylpyridine or heterocyclylpyridine derivatives, e.g. 3-phenyl-2-[(pyridin-3-yl)oxy]pyridine, 2-[(pyridin-3-yl)oxy]-3,3′-bipyridine, 5-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]isoquinoline, 8-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]quinoline, 3-(2,3-dihydrobenzofuran-7-yl)-2-[(pyridin-3-yl)oxy]pyridine, 5-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]quinoxaline, and 3-(chroman-8-yl)-2-[(pyridin-3-yl)oxy]pyridine derivatives Thus, etherification of 3-bromo-2-chloropyridine with 6-(trifluoromethyl)pyridin-3-ol in the presence of Cs2CO3 in DMSO with stirring at 120° for 18 h gave 76% 3-[(3-bromopyridin-2-yl)oxy]-6-(trifluoromethyl)pyridine (II). Coupling of II with 2-methoxyphenylboronic acid in the presence of bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]palladium(II) and Cs2CO3 in aqueous dioxane solution with stirring at 120° for 30 min under microwave irradiation gave 76% 3-(2-methoxyphenyl)-2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]pyridine (III). III showed min. inhibitory concentration of ≤0.1 μg/mL against Trichophyton mentagrophytes and T. rubrum. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Recommanded Product: 3,5-Dibromo-4-methoxypyridine

The Article related to bipyridine phenylpyridine pyridylquinoline pyrimidinylpyridine heterocyclylpyridine preparation antifungal, biaryl preparation antifungal agent, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Recommanded Product: 3,5-Dibromo-4-methoxypyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Yi, Xiao; Chen, Jing; Xu, Xiuling; Ma, Yongmin published an article in 2017, the title of the article was Solvent and substituent effects on the conversion of 4-methoxypyridines to N-methyl-4-pyridones.Formula: C6H5Br2NO And the article contains the following content:

In the reaction of 4-methoxypyridine derivatives with alkyl iodides in the presence or absence of solvent, not only the pyridinium ions but also the related 1-methylpyridones are produced. The presence of solvent favors the formation of the 1-methylpyridone. Electron withdrawing groups on the pyridine ring also favor this conversion. A possible mechanism is presented. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Formula: C6H5Br2NO

The Article related to solvent substituent effect methoxypyridine derivative alkyl iodide pyridone, Physical Organic Chemistry: Addition, Elimination, and Substitution Reactions and other aspects.Formula: C6H5Br2NO

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 6, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Formula: C6H5Br2NO The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein R4 = independently H, halo, alkyl, (un)substituted NH2, etc.; A2 = substituted Ph, pyridyl, or pyrimidinyl; A5 = substituted heterocyclyl] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Formula: C6H5Br2NO

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Formula: C6H5Br2NO

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 6, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Safety of 3,5-Dibromo-4-methoxypyridine The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein A1 = H, substituted aryl, aryloxymethyl, etc.; A2 = substituted Ph, pyridyl, pyrimidinyl, or pyrazolyl; A3 = H, arylamino, substituted heteroaryl, etc.; A5 = substituted heterocyclyl; with the proviso that at least one of A1 or A3 is H] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Safety of 3,5-Dibromo-4-methoxypyridine

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 3,5-Dibromo-4-methoxypyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 7, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Application of 25813-24-5 The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein A1 = H, substituted aryl, aryloxymethyl, etc.; A2 = substituted Ph, pyridyl, pyrimidinyl, or pyrazolyl; A3 = H, arylamino, substituted heteroaryl, etc.; A5 = substituted heterocyclyl; with the proviso that at least one of A1 or A3 is H] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Application of 25813-24-5

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem